Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Takes First Steps In India, But How Far Will It Go?

This article was originally published in PharmAsia News

Executive Summary

Takeda’s plans for India are slowly taking shape, but whether it will gain speed via buyouts or go the brick- and-mortar route is the big question.

You may also be interested in...

From Product Launches To Toll Manufacturing, Japanese Giant Takeda Unveils Plans For India

MUMBAI - Almost a year after naming former Roche executive Shankar Suryanarayanan as head of its Indian operations, Japan's largest drug maker Takeda has unveiled "medium- to long-term strategies" for its business expansion - one of which is to launch its products in the burgeoning Indian market

Indian Companies Are Becoming More Creative, Says Astellas India Managing Director Teruo Yasufuku: An Interview With PharmAsia News

Teruo Yasufuku, managing director for Astellas Pharma India, is soft-spoken and carefully measures every answer that he shares with the media. But the law graduate who started his career as a medical representative with Fujisawa in 1983 has been recognized for his leadership skills and the enthusiasm to be the best in the business. Terry, as he is called by his Indian industry contemporaries, can tirelessly talk about Prograf (tacrolimus) - Astellas' flagship transplant brand that notches worldwide sales upwards of $2 billion many years after it has been copied by generic companies. Yasufuku, along with his marketing director Himanshu Dave, proudly point at the back of their business cards, which say 'I Pledge To Donate - kidney, liver, heart, lung, pancreas, corneas.' This, Yasufuku asserts, is Astellas' unflinching commitment to the transplant segment. And, although it is a late entrant and faces intense generic competition, Prograf has a long roadmap laid out for growth in India. Yasufuku shares his wide angle on Astellas' India strategy with PharmAsia News India bureau.

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts